- Home
- ENSC vs VIVS Comparison
ENSC vs VIVS Comparison
Compare ENSC & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- VIVS
- Stock Information
- Founded
- ENSC 2003
- VIVS 2007
- Country
- ENSC United States
- VIVS United States
- Employees
- ENSC N/A
- VIVS N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENSC Health Care
- VIVS Health Care
- Exchange
- ENSC Nasdaq
- VIVS Nasdaq
- Market Cap
- ENSC 4.9M
- VIVS 4.2M
- IPO Year
- ENSC N/A
- VIVS N/A
- Fundamental
- Price
- ENSC $2.22
- VIVS $1.45
- Analyst Decision
- ENSC
- VIVS
- Analyst Count
- ENSC 0
- VIVS 0
- Target Price
- ENSC N/A
- VIVS N/A
- AVG Volume (30 Days)
- ENSC 230.3K
- VIVS 64.3K
- Earning Date
- ENSC 08-13-2025
- VIVS 07-07-2025
- Dividend Yield
- ENSC N/A
- VIVS N/A
- EPS Growth
- ENSC N/A
- VIVS N/A
- EPS
- ENSC N/A
- VIVS N/A
- Revenue
- ENSC $6,224,081.00
- VIVS $144,000.00
- Revenue This Year
- ENSC N/A
- VIVS $42.38
- Revenue Next Year
- ENSC $1,381.48
- VIVS $15.42
- P/E Ratio
- ENSC N/A
- VIVS N/A
- Revenue Growth
- ENSC 256.35
- VIVS 32.11
- 52 Week Low
- ENSC $1.62
- VIVS $1.41
- 52 Week High
- ENSC $14.67
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- ENSC 49.53
- VIVS N/A
- Support Level
- ENSC $2.02
- VIVS N/A
- Resistance Level
- ENSC $2.30
- VIVS N/A
- Average True Range (ATR)
- ENSC 0.14
- VIVS 0.00
- MACD
- ENSC 0.02
- VIVS 0.00
- Stochastic Oscillator
- ENSC 43.40
- VIVS 0.00
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.